Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Eur J Clin Pharmacol

Search In Journal Title:

Abbravation: European Journal of Clinical Pharmacology

Search In Journal Abbravation:

Publisher

Springer-Verlag

Search In Publisher:

DOI

10.1007/978-1-4615-2996-5_8

Search In DOI:

ISSN

1432-1041

Search In ISSN:
Search In Title Of Papers:

Merck fellowships contribute to the continued grow

Authors: Folke Sjöqvist LarsOlof Eriksson KarlErik Andersson
Publish Date: 2007/01/18
Volume: 63, Issue: 3, Pages: 229-231
PDF Link

Abstract

Since 1990 Merck Sharpe Dohme Sweden has created fellowships for physicians embarking upon a career in clinical pharmacology at Swedish medical schools The fellowship has provided full salary at the level of a resident in clinical medicine for an average period of 1–2 years Between 1992 and 2004 22 fellows representing all six medical schools were selected for a fellowship Of these 20 have received specialties in clinical pharmacology 11 now 2006 have positions as physicians in clinical pharmacology in university hospitals 7 in the pharmaceutical industry and 2 in a drug control agency Two have not yet completed their training The fellowships have been granted on the basis of excellence in clinical pharmacological problemoriented research The peer review of the applications has been performed by academic professors in clinical pharmacology and the chairperson of the Swedish Society of Clinical Pharmacology The importance of having a donor with serious dedication to training and research and a scholarship organization that can prioritize these goals in an unbiased way are underlined The Swedish MSD fellowships are a valuable complement to the resources provided by society to support the development of clinical pharmacology ie the health care organizations the faculties in medicine and various research foundations

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Real-time RT-PCR methodology for quantification of thiopurine methyltransferase gene expression
  2. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients
  3. Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson’s patients
  4. Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring
  5. Antibiotic prescription and prevalence rate in the outpatient paediatric population: analysis of surveys published during 2000–2005
  6. Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women
  7. Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155)
  8. Incidence and risk factors for nevirapine-associated rash
  9. Case series: paradoxical action of domperidone leads to increased vomiting
  10. Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures
  11. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine
  12. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients
  13. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU
  14. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response
  15. Laxative treatment elevates plasma homocysteine: a study on a population-based Swedish sample of old people
  16. Clinical pharmacology of melatonin in the treatment of tinnitus: a review
  17. Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24
  18. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals
  19. Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not
  20. Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not
  21. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling
  22. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
  23. Clinical trials during pregnancy: what has been done
  24. Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore
  25. Pharmacokinetic–pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide
  26. Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects
  27. A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia
  28. Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events
  29. Comparison of rational pharmacotherapy decision-making competence of general practitioners with intern doctors
  30. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations
  31. Pharmacokinetic study of the interaction between itraconazole and nevirapine
  32. Mirtazapine in drug-induced excessive sweating
  33. Population pharmacokinetic analysisof lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART
  34. Diosmin pretreatment affects bioavailability of metronidazole
  35. Associations between CYP2E1 promoter polymorphisms and plasma 1,3-dimethyluric acid/theophylline ratios
  36. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis
  37. Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies—a systematic review
  38. Early discontinuation: more frequent among general practitioners with high levels of prescribing
  39. Stimulation of endothelial progenitor cells: a new putative effect of several cardiovascular drugs
  40. Influence of bariatric surgery on the use of medication
  41. Medical speciality and pattern of medicines prescription
  42. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes
  43. Herbal medicines – they are popular, but are they also safe?
  44. Restricted indications for the use of antibiotics in acute otitis media
  45. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands
  46. The effect of acarbose on the pharmacokinetics of rosiglitazone
  47. Use of psychotropics is high among very old people
  48. Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation
  49. Prevalence of statin-drug interactions in older people: a systematic review
  50. Vitamin D deficiency as adverse drug reaction? A cross-sectional study in Dutch geriatric outpatients
  51. Use of anti-asthmatic drugs during pregnancy. 1. Maternal characteristics, pregnancy and delivery complications
  52. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
  53. Oral quinine pharmacokinetics and dietary salt intake
  54. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis
  55. Children’s presence in research. A review of online registers
  56. Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers
  57. Evidence of safety of chloral hydrate for prolonged sedation in PICU in a tertiary teaching hospital in southern Brazil
  58. Genistein alters caffeine exposure in healthy female volunteers
  59. Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System
  60. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects
  61. Novel strategies for the treatment of inflammatory hyperalgesia
  62. Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review
  63. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing
  64. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing
  65. Rifampicin markedly decreases the exposure to oral and intravenous tramadol
  66. Potentially inappropriate prescribing in elderly outpatients in Croatia
  67. Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage
Search Result: